Plain-English translation of NCT06893965 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
This study doesn't follow the usual testing phases โ it may be an observational study or a different type of research.
This trial is testing a new, higher-concentration version of Aflibercept 8mg/0.07mL โ a medication injected into the eye to treat macular diseases. Researchers want to understand how this stronger dose affects eye pressure immediately after injection and whether repeated injections over time cause any long-term damage to the eye's nerve layer.
The new treatment uses a larger injection volume than older versions, which may temporarily raise eye pressure inside the eye more than before. Doctors don't yet know how high the pressure will go, how quickly it returns to normal, or what happens to patients' eyes over time with repeated injections โ so this study will measure these important safety questions.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will receive your scheduled eye injection as normal during a routine clinic visit. During and after the injection, doctors will measure your eye pressure five times over 45 minutes using a special instrument to check if pressure spikes occur. You will also have an eye scan (OCT) before the injection and again at 12 months to look for any long-term changes. Your regular treatment plan will not change โ this is purely monitoring to collect safety information.
AI-generated summary from trial data ยท Jul 15, 2026 ยท Not medical advice
France